Alto Neuroscience, Inc. (ANRO)

Combines neuroscience and artificial intelligence to develop precision therapies for mental health conditions.

ANRO Stock Quote

Company Report

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprises ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.

In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient.

The company was incorporated in 2019 and is headquartered in Los Altos, California.

ANRO EPS Chart

ANRO Revenue Chart

Stock Research

LSXMK ESAC YRD LPTX OFS LOGI ARQQ

ANRO Chart

View interactive chart for ANRO

ANRO Profile

ANRO News

Analyst Ratings